Ansa

Ansa is a technology company.

Active

Updated: Dec 10, 2025 ·

Recent News & Mentions

Apr 1, 2024FundingAnsa - Series A Apr 1, 2023FundingAnsa - Seed

Financial History

Ansa has raised $19.0M across 2 funding rounds. Most recently, it raised $14.0M Series A in April 2024.

Total Raised

$19.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Lead Investors	Other Investors
Apr 1, 2024	$14.0M Series A		Andreessen Horowitz, Jana Messerschmidt, TJ Nahigian, BoxGroup, Buckley Ventures, Byers Capital, Cambrian Ventures, Digital Currency Group, Dragonfly Capital Partners, ENIAC Ventures, Founders' Co-op, General Catalyst, Khosla Ventures, KRM Interests LLC, Lightbank, Mischief Venture Capital, Nyca Partners, Red Swan Ventures, Renegade Partners, Balaji Srinivasan, Gokul Rajaram, Gordon Wintrob, Julian Koh, Louis Beryl, Nikhil Krishnan, Zak Kukoff
Apr 1, 2023	$5.0M Seed		AAF Management Ltd., AirAngels, Andreessen Horowitz, TJ Nahigian, BoxGroup, Buckley Ventures, Byers Capital, Cambrian Ventures, Daffy, Fin Capital, General Catalyst, Humba Ventures, Mischief Venture Capital, NextGen Venture Partners, PruVen Capital, QED Investors, Anthony Pompliano, Balaji Srinivasan, Dylan Field, Gokul Rajaram, Gordon Wintrob, Louis Beryl, Nikhil Krishnan, Othman Laraki, Youcef Es-skouri, Zak Kukoff

Financial History

Ansa has raised $19.0M across 2 funding rounds.

Total Raised

$19.0M

Valuation

N/A

Deep Dive

Ansa refers to multiple companies. I assume you mean Ansa Biotechnologies (the well-known enzymatic DNA-synthesis company); if you meant a different “Ansa” (payments platform Ansa.dev or AI consultancy ansa.solutions), tell me which and I’ll adapt the profile. Below is a concise investor-style/company profile of Ansa Biotechnologies.

High-Level Overview

Ansa Biotechnologies is a private biotechnology company commercializing a proprietary enzymatic DNA‑synthesis platform that enables faster, longer and higher‑complexity synthetic DNA than traditional chemical methods, targeting research and therapeutic customers in life sciences and industrial biotech.[1][6] The company sells sequence‑verified, clonal or linear double‑stranded DNA constructs (delivering constructs up to 50 kb and no‑assembly synthesis for certain short complex sequences) and positions itself as a faster, greener alternative for DNA supply in cell & gene therapy, vaccines, synthetic biology, agrigenomics and related areas[3][6]. Demand and commercial activity have grown rapidly since its launch, including enterprise collaborations and guarantee‑style service commitments to accelerate adoption and customer confidence[3][1].

Origin Story

Ansa was founded in 2018 as a spinout from the University of California, Berkeley and is headquartered in Emeryville, California[1][6]. Its technology is built on enzymatic DNA synthesis using terminal deoxynucleotidyl transferase (TdT) and polymerase‑nucleotide conjugate chemistry that lets the company synthesize DNA without the limitations of legacy chemical phosphoramidite methods[1]. Early validation included research partnerships (notably collaboration with Microsoft on DNA data storage research) and investor support that carried through a Series A in 2022 and later financing rounds including a Series B to scale operations and commercial services[1][3]. Initial traction included successful technology demonstrations, partnerships with reagent and biosecurity providers, and rapid customer demand after commercialization[1][5][3].

Core Differentiators

Proprietary enzymatic platform: Uses TdT/polymerase conjugate chemistry to produce longer and more complex sequences than conventional chemical synthesis methods, with a focus on sequence quality and sustainability[1][6].
Length & complexity capability: Public claims of delivering clonal DNA up to ~50 kilobases and no‑assembly direct synthesis for certain complex short constructs set it apart from many legacy providers[3][6].
Speed + service guarantees: Introduced an “On‑Time Guarantee” and pricing tiers to lower barriers for routine sequences while offering competitive turnaround for complex constructs[3].
Sustainability: Enzymatic approach eliminates many harsh chemicals used in traditional synthesis, which the company promotes as preserving DNA integrity and reducing environmental impact[3][1].
Biosecurity and compliance integration: Uses automated biosecurity screening and partners (e.g., Aclid) to scale secure screening workflows appropriate for pharmaceutical and regulated customers[5].
Commercial focus & customer experience: Emphasis on sequence verification, clonal delivery, and service-level commitments (and pricing options) to attract enterprise scientists and industry R&D teams[3][6].

Role in the Broader Tech / Bio Landscape

Riding the enzyme‑driven DNA synthesis trend: The company is part of a broader shift from chemical to enzymatic DNA synthesis, driven by demand for longer constructs, improved fidelity, lower environmental footprint, and cost/time efficiencies for large or complex builds[1][3].
Timing: Growth in cell & gene therapies, synthetic biology, vaccine R&D, and genomic engineering increases demand for long, accurate DNA constructs—precisely the market Ansa targets[3][6].
Market forces in its favor: Increasing outsourcing of DNA supply, proliferation of complex DNA designs (e.g., for gene circuits and therapeutic constructs), and strategic partnerships (e.g., with reagent suppliers, data‑storage research teams, and biosecurity vendors) all support adoption[1][5][3].
Influence: By enabling longer constructs and improved turnaround, Ansa lowers technical barriers for engineering biology at scale, which can accelerate discovery, lower time‑to‑clinic for therapies, and shift industry expectations for DNA vendor capabilities[3][6].

Quick Take & Future Outlook

Near term: Expect continued scale‑up of manufacturing and R&D, expanded commercial throughput, and further enterprise partnerships and pricing/product tiers to broaden addressable customers—especially in therapeutics and industrial biotech[3][1].
Medium term: If enzymatic synthesis continues to deliver on cost, fidelity and length advantages at scale, Ansa could displace portions of the legacy DNA‑supply market for complex constructs and become a preferred vendor for therapeutic and large‑scale synthetic biology projects[3][6].
Risks and shaping trends: Adoption depends on sustained manufacturing scale, consistent sequence quality, regulatory/biosecurity controls, and competition from other enzymatic synthesis startups and incumbent providers upgrading chemistry[1][3][5]. Advances in automation, reagent optimization, and partnerships with large pharma or tech (e.g., prior Microsoft collaboration) would materially accelerate the company’s influence[1][3].

If you want, I can:

Produce a 1‑page investor memo with financial milestones and known funding rounds.
Create a competitor comparison table (e.g., Twist, Genscript, Evonetix and other enzymatic synthesis startups).
Switch this profile to the other “Ansa” companies (Ansa.dev or ANSA Solutions) if that’s the intended target.

Sources

Frequently Asked Questions

How much funding has Ansa raised?

Ansa has raised $19.0M in total across 2 funding rounds.

Who are Ansa's investors?

Ansa's investors include Andreessen Horowitz, Jana Messerschmidt, TJ Nahigian, BoxGroup, Buckley Ventures, Byers Capital, Cambrian Ventures, Digital Currency Group, Dragonfly Capital Partners, ENIAC Ventures, Founders' Co-op, General Catalyst.